Assenagon Asset Management S.A. Has $166.09 Million Holdings in Cencora, Inc. $COR

Assenagon Asset Management S.A. raised its position in shares of Cencora, Inc. (NYSE:COR) by 129.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 586,914 shares of the company’s stock after buying an additional 331,340 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Cencora were worth $166,085,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Apollon Wealth Management LLC raised its holdings in shares of Cencora by 0.5% during the fourth quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock valued at $2,205,000 after acquiring an additional 30 shares during the period. Accent Capital Management LLC boosted its stake in Cencora by 36.1% in the 4th quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock worth $38,000 after purchasing an additional 30 shares during the period. MCF Advisors LLC boosted its stake in Cencora by 11.0% in the 4th quarter. MCF Advisors LLC now owns 303 shares of the company’s stock worth $102,000 after purchasing an additional 30 shares during the period. CYBER HORNET ETFs LLC grew its position in Cencora by 6.8% during the 4th quarter. CYBER HORNET ETFs LLC now owns 485 shares of the company’s stock worth $164,000 after purchasing an additional 31 shares in the last quarter. Finally, Steph & Co. grew its position in Cencora by 23.5% during the 1st quarter. Steph & Co. now owns 168 shares of the company’s stock worth $53,000 after purchasing an additional 32 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on COR. William Blair began coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating for the company. Bank of America lifted their price target on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a report on Wednesday, June 24th. Robert W. Baird set a $370.00 price target on Cencora in a research report on Thursday. Evercore reissued an “outperform” rating and issued a $350.00 price objective on shares of Cencora in a research note on Thursday. Finally, Barclays decreased their price objective on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Eleven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $371.00.

Key Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Quarterly earnings beat estimates. Cencora reported adjusted diluted EPS of $4.48, up from $4.00 a year ago and above the roughly $4.35-$4.37 analyst consensus. Revenue rose 5.1% year over year to approximately $84.8 billion, slightly exceeding expectations. Cencora Reports Fiscal 2026 Third Quarter Results
• Positive Sentiment: Management raised its fiscal 2026 adjusted EPS outlook to $17.75-$17.95 from $17.70-$17.90, while maintaining its approximately $3 billion free-cash-flow target. The guidance increase signals confidence in continued operating momentum. Cencora outlines fiscal 2026 EPS of $17.75-$17.95
• Positive Sentiment: Specialty pharmaceuticals remained the main growth driver. Strength in U.S. Healthcare Solutions, international operations and OneOncology helped support profit growth, while the company repurchased approximately $1 billion of stock during the quarter, potentially boosting per-share results. Cencora lifts annual profit view on strong demand for specialty medicines
• Positive Sentiment: Cencora declared a quarterly dividend of $0.60 per share, payable August 31 to shareholders of record August 14. The dividend is modest, with an annualized yield of about 0.7%, but reinforces the company’s capital-return program.

Cencora Price Performance

COR opened at $325.02 on Friday. The stock has a fifty day moving average price of $292.86 and a 200 day moving average price of $314.37. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 3.53. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a market cap of $63.24 billion, a price-to-earnings ratio of 24.15, a PEG ratio of 1.76 and a beta of 0.57.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%.The company had revenue of $84.75 billion for the quarter, compared to analyst estimates of $84.31 billion. During the same period in the prior year, the firm posted $4.00 EPS. The business’s revenue was up 5.1% compared to the same quarter last year. Analysts forecast that Cencora, Inc. will post 17.8 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be issued a $0.60 dividend. The ex-dividend date is Friday, August 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is currently 17.83%.

Cencora declared that its board has authorized a share repurchase plan on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other Cencora news, Director Lauren M. Tyler acquired 550 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were purchased at an average price of $270.23 per share, with a total value of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares in the company, valued at $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.38% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.